您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > O-1602
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
O-1602
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
O-1602图片
CAS NO:317321-41-8
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍

GPR55 cannabinoid receptor agonist

Cas No.317321-41-8
别名Abn-CBDO, Abnormal Cannabidiorcin, Abnormal Cannabidiorcinol, Abnormal Cannabiorcodiol
化学名(1'R,2'R)-5',6-dimethyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,4-diol
Canonical SMILESOC1=C(C(C)=CC(O)=C1)[C@H]2[C@H](C(C)=C)CCC(C)=C2
分子式C17H22O2
分子量258.36
溶解度DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2)(1:1): 5 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

O-1602 is an agonist of GPR55 (EC50 = 13 nM in a GTPγS binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol.[1] It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 μM for both in GTPγS binding assays). O-1602 (50 μM) reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz-ChA-1 mouse xenograft model when administered at a dose of 10 mg/kg per day.[2] O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a concentration-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55.[3] O-1602 reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain.[4] It also decreases IL-6 and TNF-α levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis.[5]

Reference:
[1]. Ryberg, E., Larsson, N., Sjogren, S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152(7), 1092-1101 (2007).
[2]. Huang, L., Ramirez, J.C., Frampton, G.A., et al. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest. 91(7), 1007-1017 (2011).
[3]. Díaz-Arteaga, A., Vázquez, M.J., Vazquez-Martínez, R., et al. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes. Metab. 14(3), 234-243 (2012).
[4]. Schuelert, N., and Mcdougall, J.J. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Nuerosci. Lett. 500(1), 72-76 (2011).
[5]. Li, K., Feng, J.-Y., Li, Y.-Y., et al. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas 42(1), 123-129 (2013).